Quality of life with trabectedin
•
Patients reported outcomes (PRO)
from the randomized phase III
study comparing trabectedin
vs
. dacarbazine in advanced
leiomyosarcoma and liposarcoma
:
•
No clinically
meaningful
differences
between the two
treatment groups.
Patients receiving trabectedin can maintain good functional
performance and low symptom burden for prolonged periods.
Demetri GD, et al. J Clin Oncol 34, 2016 (suppl; abstr 11061)
